Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 26;6(6):CD015851.
doi: 10.1002/14651858.CD015851.

Sorafenib with or without co-interventions for hepatocellular carcinoma

Shanshan Chen  1 , Jian Ping Liu  2 , Xinyu Li  1 , Shoutao Dang  1 , Wei Li  1
Affiliations
Review

Sorafenib with or without co-interventions for hepatocellular carcinoma

Shanshan Chen et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the beneficial and harmful effects of sorafenib, with or without co-interventions, versus placebo, no intervention, or the same co-interventions for adults, aged 18 and over, with hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Shanshan Chen has no conflicts of interest. Jian‐Ping Liu is an editor of the Cochrane Hepato‐Biliary Group, but he was not involved in any of the editorial decisions related to this protocol. Xinyu Li has no conflicts of interest. Shoutao Dang has no conflicts of interest. Wei Li has no conflicts of interest.

Similar articles

See all similar articles

References

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993;85(5):365-76. [DOI: 10.1093/jnci/85.5.365] - DOI - PubMed
Abdel‐Rahman 2014
    1. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Critical Reviews in Oncology Hematology 2014;91(1):1-8. [DOI: 10.1016/j.critrevonc.2013.12.013] - DOI - PubMed
Akinyemiju 2017
    1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease study 2015. JAMA Oncology 2017;3(12):1683-91. [DOI: 10.1001/jamaoncol.2017.3055] - DOI - PMC - PubMed
Baek 2011
    1. Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011;80(3-4):167-74. [DOI: 10.1159/000327591] - DOI - PubMed
Brown 2023
    1. Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surgery 2023;158(4):410-20. [DOI: 10.1001/jamasurg.2022.7989] - DOI - PubMed
Bruix 2012
    1. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of Hepatology 2012;57(4):821-9. [DOI: 10.1016/j.jhep.2012.06.014] - DOI - PubMed
Bruix 2015
    1. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology 2015;16(13):1344-54. [DOI: 10.1016/S1470-2045(15)00198-9] - DOI - PubMed
Bucalau 2021
    1. Bucalau AM, Tancredi I, Verset G. In the era of systemic therapy for hepatocellular carcinoma Is transarterial chemoembolization still a card to play? Cancers 2021;13(20):5129. [DOI: 10.3390/cancers13205129] - DOI - PMC - PubMed
Buscarini 2005
    1. Buscarini E, Savoia A, Brambilla G, Menozzi F, Reduzzi L, Strobel D, et al. Radiofrequency thermal ablation of liver tumors. European Radiology 2005;15(5):884-94. [DOI: 10.1007/s00330-005-2652-x] - DOI - PubMed
Cabibbo 2013
    1. Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Review of Anticancer Therapy 2013;13(12):1355-61. [DOI: 10.1586/14737140.2013.859989] - DOI - PubMed
Cai 2017
    1. Cai R, Song RF, Pang PF, Yan Y, Liao YF, Zhou CL, et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. BMC Cancer 2017;17(1):714. [DOI: 10.1186/s12885-017-3707-5] - DOI - PMC - PubMed
Castellini 2018
    1. Castellini G, Bruschettini M, Gianola S, Gluud C, Moja L. Assessing imprecision in Cochrane systematicreviews: a comparison of GRADE and trial sequential analysis. Systematic Reviews 2018;7(110):1-10. [DOI: 10.1186/s13643-018-0770-1] - DOI - PMC - PubMed
Cauchy 2014
    1. Cauchy F, Soubrane O, Belghiti J. Liver resection for HCC: patient's selection and controversial scenarios. Best Practice & Research Clinical Gastroenterology 2014;28(5):881-96. [DOI: 10.1016/j.bpg.2014.08.013] - DOI - PubMed
Cella 1993
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993;11(3):570-9. [DOI: 10.1200/JCO.1993.11.3.570] - DOI - PubMed
Chang 2020
    1. Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. International Journal of Molecular Sciences 2020;21(21):8165. [DOI: 10.3390/ijms21218165] - DOI - PMC - PubMed
Chapiro 2014
    1. Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: is there a clinical benefit? Radiologia Medica 2014;119(7):476-82. [DOI: 10.1007/s11547-014-0413-0] - DOI - PubMed
Chen 2016
    1. Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 2016;7(51):85450-63. [DOI: 10.18632/oncotarget.13398] - DOI - PMC - PubMed
Chen 2022
    1. Chen TT, Liu JL, Li YL, Wei S. Burden of disease associated with dietary exposure to aflatoxins in China in 2020. Nutrients 2022;14(5):1027. [DOI: 10.3390/nu14051027] - DOI - PMC - PubMed
Chen 2023
    1. Chen CB, Chen CM, Tzeng RH, Chou CT, Su PY, Hsu YC, et al. Combining HAIC and sorafenib as a salvage treatment for patients with treatment-failed or advanced hepatocellular carcinoma: a single-center experience. Journal of Clinical Medicine 2023;12(5):1887. [DOI: 10.3390/jcm12051887] - DOI - PMC - PubMed
Cheng 2009
    1. Cheng AL, Kang YK, Chen ZD, Tsao CJ, Qin SK, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009;10(1):25-34. [DOI: 10.1016/S1470-2045(08)70285-7] - DOI - PubMed
Cheng 2022
    1. Cheng CC, Ho AS, Peng CL, Chang J, Sie ZL, Wang CL, et al. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. International Immunopharmacology 2022;112:109110. [DOI: 10.1016/j.intimp.2022.109110] - DOI - PubMed
Choi 2019
    1. Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology 2019;25(20):2416-29. [DOI: 10.3748/wjg.v25.i20.2416] - DOI - PMC - PubMed
Ciria 2016
    1. Ciria R, Cherqui D, Geller DA, Briceno J, Wakabayashi G. Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. Annals of Surgery 2016;263(4):761-77. [DOI: 10.1097/SLA.0000000000001413] - DOI - PubMed
Ciria 2022
    1. Ciria R, Berardi G, Alconchel F, Briceño J, Choi GH, Wu YM, et al. The impact of robotics in liver surgery: a worldwide systematic review and short-term outcomes meta-analysis on 2,728 cases. Journal of Hepato-Biliary-Pancreatic Sciences 2022;29(2):181-97. [DOI: 10.1002/jhbp.869] - DOI - PubMed
Covidence [Computer program]
    1. Covidence systematic review software. Version accessed 23 January 2025. Melbourne, Australia: Veritas Health Innovation, 2025. Available at www.covidence.org.
Crocetti 2008
    1. Crocetti L, Lencioni R. Thermal ablation of hepatocellular carcinoma. Cancer Imaging 2008;8(1):19-26. [DOI: 10.1102/1470-7330.2008.0004] - DOI - PMC - PubMed
Da Fonseca 2020
    1. Da Fonseca LG, Reig M, Bruix J. Tyrosine kinase inhibitors and hepatocellular carcinoma. Clinics in Liver Disease 2020;24(4):719-37. [DOI: 10.1016/j.cld.2020.07.012] - DOI - PubMed
Daniele 2004
    1. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):108-12. [DOI: 10.1053/j.gastro.2004.09.023] - DOI - PubMed
Deeks 2024
    1. Deeks JJ, Higgins JP, Altman DG, McKenzie JE, Veroniki AA (editors). Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Di Marco 2013
    1. Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C. Sorafenib: from literature to clinical practice. Annals of Oncology 2013;24(Suppl 2):30-7. [DOI: 10.1093/annonc/mdt055] - DOI - PubMed
Du 2018
    1. Du ZF, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer 2018;17(1):58. [DOI: 10.1186/s12943-018-0782-4] - DOI - PMC - PubMed
Duseja 2014
    1. Duseja A. Staging of hepatocellular carcinoma. Journal of Clinical and Experimental Hepatology 2014;4(Suppl 3):S74-9. [DOI: 10.1016/j.jceh.2014.03.045] - DOI - PMC - PubMed
EASL 2018
    1. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2018;69(1):182-236. [DOI: 10.1016/j.jhep.2018.03.019] - DOI - PubMed
Ebara 2005
    1. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. Journal of Hepatology 2005;43(3):458-64. [DOI: 10.1016/j.jhep.2005.03.033] - DOI - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629] - DOI - PMC - PubMed
El‐Khoueiry 2017
    1. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492-502. [DOI: 10.1016/S0140-6736(17)31046-2] - DOI - PMC - PubMed
El‐Serag 2008
    1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134(6):1752-63. [DOI: 10.1053/j.gastro.2008.02.090] - DOI - PubMed
Fan 2024
    1. Fan W, Zhu B, Chen S, Wu Y, Zhao X, Qiao L, et al. Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial. JAMA Oncology 2024;10(8):1047-54. [DOI: 10.1001/jamaoncol.2024.1831] - DOI - PMC - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10. [DOI: 10.1016/j.jclinepi.2005.06.006] - DOI - PubMed
Galmiche 2014
    1. Galmiche A, Chauffert B, Barbare JC. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Letters 2014;346(2):159-62. [DOI: 10.1016/j.canlet.2013.12.028] - DOI - PubMed
Gartlehner 2019
    1. Gartlehner G, Nussbaumer-Streit B, Wagner G, Patel S, Swinson-EvansT, Dobrescu A, et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology 2019;106:50-9. [DOI: 10.1016/j.jclinepi.2018.10.009] - DOI - PubMed
Gluud 2006
    1. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163(6):493-501. [DOI: 10.1093/aje/kwj069] - DOI - PubMed
Goldberg 2003
    1. Goldberg SN, Charboneau JW, Dodd GD, Dupuy DE, Gervais DA, Gillams AR, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003;228(2):335-45. [DOI: 10.1148/radiol.2282021787] - DOI - PubMed
Gordan 2024
    1. Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. Journal of Clinical Oncology 2024;42(15):1830-50. [DOI: 10.1200/JCO.23.02745] - DOI - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 18 April 2024. Hamilton (ON): McMaster University (developed by Evidence Prime), 2024. Available at gradepro.org.
Gregory 2020
    1. Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Reports 2020;2(3):100100. [DOI: 10.1016/j.jhepr.2020.100100] - DOI - PMC - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence – study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [DOI: 10.1016/j.jclinepi.2010.07.017] - DOI - PubMed
Gyawali 2017
    1. Gyawali B, Shimokata T, Ando M, Honda K, Ando Y. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Annals of Oncology 2017;28(2):246-53. [DOI: 10.1093/annonc/mdw549] - DOI - PubMed
Haber 2021
    1. Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology 2021;161(3):879-98. [DOI: 10.1053/j.gastro.2021.06.008] - DOI - PubMed
He 2019
    1. He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncology 2019;5(7):953-60. [DOI: 10.1001/jamaoncol.2019.0250] - DOI - PMC - PubMed
Higgins 2024a
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Higgins 2024b
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Higgins 2024c
    1. Higgins JP, Eldridge S, Li T. Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Higgins 2024d
    1. Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Ho 2014
    1. Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB 2014;16(8):758-67. [DOI: 10.1111/hpb.12214] - DOI - PMC - PubMed
Hollis 1999
    1. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [DOI: 10.1136/bmj.319.7211.670] - DOI - PMC - PubMed
Hsieh 2020
    1. Hsieh MH, Kao TY, Hsieh TH, Kao CC, Peng CY, Lai HC, et al. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. PLOS One 2020;15(12):e0244293. [DOI: 10.1371/journal.pone.0244293] - DOI - PMC - PubMed
Huang 2000
    1. Huang J, He X, Lin X, Zhang C, Li J. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chinese Medical Journal 2000;113(5):446-8. - PubMed
Huang 2013
    1. Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, et al. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. International Journal of Radiation Oncology Biology Physics 2013;86(3):456-62. [DOI: 10.1016/j.ijrobp.2013.01.025] - DOI - PubMed
Huang 2019
    1. Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q. Supplementary sorafenib therapies for hepatocellular carcinoma – a systematic review and meta-analysis: supplementary sorafenib for liver cancer. Journal of Clinical Gastroenterology 2019;53(7):486-94. [DOI: 10.1097/MCG.0000000000001175] - DOI - PubMed
Huang 2021
    1. Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology 2021;19(1):168. [DOI: 10.1186/s12957-021-02280-9] - DOI - PMC - PubMed
Iavarone 2011
    1. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54(6):2055-63. [DOI: 10.1002/hep.24644] - DOI - PubMed
ICH 2016
    1. International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). database.ich.org/sites/default/files/E6_R2_Addendum.pdf (accessed 13 May 2025).
Iezzi 2016
    1. Iezzi R, Pompili M, Posa A, Coppola G, Gasbarrini A, Bonomo L. Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art. World Journal of Gastroenterology 2016;22(6):1935-42. [DOI: 10.3748/wjg.v22.i6.1935] - DOI - PMC - PubMed
Jakobsen 2014
    1. Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14:120. [DOI: 10.1186/1471-2288-14-120] - DOI - PMC - PubMed
Jiang 2024
    1. Jiang Z, Yang F, Wang W. Applications of yttrium-90 (90Y) in hepatocellular carcinoma. OncoTargets and Therapy 2024;17:149-57. [DOI: 10.2147/OTT.S445898] - DOI - PMC - PubMed
Keane 2016
    1. Keane FK, Wo JY, Zhu AX, Hong TS. Liver-directed radiotherapy for hepatocellular carcinoma. Liver Cancer 2016;5(3):198-209. [DOI: 10.1159/000367764] - DOI - PMC - PubMed
Kim 2015
    1. Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2015;9(3):335-48. [DOI: 10.1586/17474124.2015.959929] - DOI - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. - PubMed
Kong 2016
    1. Kong WT, Cai H, Tang Y, Zhang XL, Wang WP. Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. Discovery Medicine 2016;21(118):459-68. - PubMed
Kudo 2020
    1. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69(8):1492-501. [DOI: 10.1136/gutjnl-2019-318934] - DOI - PMC - PubMed
Labeur 2018
    1. Labeur TA, Ten Cate DW, Takkenberg RB, Azahaf H, Oijen MG, Delden OM, et al. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. Acta Oncologica 2018;57(11):1467-74. [DOI: 10.1080/0284186X.2018.1479070] - DOI - PubMed
Lau 2010
    1. Lau WY, Lai EC, Lau SH. Methods of vascular control technique during liver resection: a comprehensive review. Hepatobiliary & Pancreatic Diseases International 2010;9(5):473-81. - PubMed
Lefebvre 2024
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies (last updated September 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Lefebvre 2025
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies (last updated March 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1 Cochrane, 2025. Available from www.training.cochrane.org/handbook.
Lencioni 2010
    1. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Disease 2010;30(1):52-60. [DOI: 10.1055/s-0030-1247132] - DOI - PubMed
Li 2023
    1. Li H, Wu Z, Chen J, Su K, Guo L, Xu K, et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clinical and Experimental Medicine 2023;23(5):1537-49. [DOI: 10.1007/s10238-022-00972-4] - DOI - PMC - PubMed
Liu 2020
    1. Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Annals of Translational Medicine 2020;8(9):583. [DOI: 10.21037/atm.2020.03.71] - DOI - PMC - PubMed
Livraghi 2008
    1. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47(1):82-9. [DOI: 10.1002/hep.21933] - DOI - PubMed
Llovet 2008
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008;359(4):378-90. [DOI: 10.1056/NEJMoa0708857] - DOI - PubMed
Llovet 2020
    1. Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. Journal of Hepatology 2020;72(2):288-306. [DOI: 10.1016/j.jhep.2019.09.026] - DOI - PubMed
Llovet 2021a
    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers 2021;7(1):6. [DOI: 10.1038/s41572-020-00240-3] - DOI - PubMed
Llovet 2021b
    1. Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 2021;18(5):293-313. [DOI: 10.1038/s41575-020-00395-0] - DOI - PubMed
Long 2023
    1. Long Y, Song X, Guan Y, Lan R, Huang Z, Li S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology 2023;38(4):486-95. [DOI: 10.1111/jgh.16088] - DOI - PubMed
Lundh 2017
    1. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] - DOI - PMC - PubMed
Makuuchi 1998
    1. Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, et al. Hepatic resection for hepatocellular carcinoma – Japanese experience. Hepato-gastroenterology 1998;45(Suppl 3):1267-74. - PubMed
Marrero 2016
    1. Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. Journal of Hepatology 2016;65(6):1140-7. [DOI: 10.1016/j.jhep.2016.07.020] - DOI - PubMed
Marrero 2020
    1. Marrero JA. Surveillance for hepatocellular carcinoma. Clinics in Liver Disease 2020;24(4):611-21. [DOI: 10.1016/j.cld.2020.07.013] - DOI - PubMed
Maruyama 2023
    1. Maruyama H, Tobari M, Nagamatsu H, Yamaguchi T, Shiina S. Ablation for benign liver tumors: current concepts and limitations. Journal of Clinical and Translational Hepatology 2023;11(1):244-52. [DOI: 10.14218/JCTH.2022.00205] - DOI - PMC - PubMed
Mathew 2020
    1. Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. European Journal of Cancer 2020;134:41-51. [DOI: 10.1016/j.ejca.2020.04.024] - DOI - PMC - PubMed
McGlynn 2021
    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73(Suppl 1):4-13. [DOI: 10.1002/hep.31288] - DOI - PMC - PubMed
McKenzie 2024
    1. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
McNamara 2018
    1. McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma – a meta-analysis. European Journal of Cancer 2018;105:1-9. [DOI: 10.1016/j.ejca.2018.09.031] - DOI - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352(9128):609-13. [DOI: 10.1016/S0140-6736(98)01085-X] - DOI - PubMed
Nahm 2023
    1. Nahm WJ, Bhatt A, Wu J. Role of radiotherapy and its contribution to immunotherapy in hepatocellular carcinoma. Chinese Clinical Oncology 2023;12(4):41. [DOI: 10.21037/cco-23-50] - DOI - PubMed
Nakabori 2024
    1. Nakabori T, Ikawa T, Kozumi K, Urabe M, Kai Y, Takada R, et al. Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy. Clinical Journal of Gastroenterology 2024;17(6):1053-7. [DOI: 10.1007/s12328-024-02030-w] - DOI - PubMed
Nault 2018
    1. Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. Journal of Hepatology 2018;68(4):783-97. [DOI: 10.1016/j.jhep.2017.10.004] - DOI - PubMed
Niu 2014
    1. Niu LZ, Li JL, Xu KC. Percutaneous cryoablation for liver cancer. Journal of Clinical and Translational Hepatology 2014;2(3):182-8. [DOI: 10.14218/JCTH.2014.00017] - DOI - PMC - PubMed
Omyła‐Staszewska 2012
    1. Omyła-Staszewska J, Deptała A. Effective therapeutic management of hepatocellular carcinoma – on the basis of a clinical case. Contemporary Oncology 2012;16(1):60-3. [DOI: 10.5114/wo.2012.27339] - DOI - PMC - PubMed
Orcutt 2018
    1. Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control 2018;25(1):1073274817744621. [DOI: 10.1177/1073274817744621] - DOI - PMC - PubMed
Page 2021a
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. [DOI: 10.1136/bmj.n71] - DOI - PMC - PubMed
Page 2021b
    1. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. [DOI: 10.1136/bmj.n160] - DOI - PMC - PubMed
Page 2024
    1. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Payo‐Serafín 2024
    1. Payo-Serafín T, Méndez-Blanco C, Fernández-Palanca P, Martínez-Geijo J, Reviejo M, Ortiz-de-Urbina JJ, et al. Risk versus benefit of tyrosine kinase inhibitors for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Clinical Pharmacology and Therapeutics 2024;116(2):328-45. [DOI: 10.1002/cpt.3312] - DOI - PubMed
Petrick 2020
    1. Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. International Journal of Cancer 2020;147(2):317-30. [DOI: 10.1002/ijc.32723] - DOI - PMC - PubMed
Petrillo 2018
    1. Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, et al. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncology 2018;14(28):2957-67. [DOI: 10.2217/fon-2017-0739] - DOI - PubMed
Pinyol 2019
    1. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68(6):1065-75. [DOI: 10.1136/gutjnl-2018-316408] - DOI - PMC - PubMed
Pugh 1973
    1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery 1973;60(8):646-9. [DOI: 10.1002/bjs.1800600817] - DOI - PubMed
Qin 2014
    1. Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 2014;19(11):1169-78. [DOI: 10.1634/theoncologist.2014-0190] - DOI - PMC - PubMed
Qin 2016
    1. Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepatic Oncology 2016;3(1):71-81. [DOI: 10.2217/hep.15.42] - DOI - PMC - PubMed
Rabin 2001
    1. Rabin R, Charro F. EQ-5D: a measure of health status from the EuroQol Group. Annals of Medicine 2001;33(5):337-43. [DOI: 10.3109/07853890109002087] - DOI - PubMed
Raoul 2019
    1. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treatment Reviews 2019;72:28-36. [DOI: 10.1016/j.ctrv.2018.11.002] - DOI - PubMed
Reig 2022
    1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. Journal of Hepatology 2022;76(3):681-93. [DOI: 10.1016/j.jhep.2021.11.018] - DOI - PMC - PubMed
Renzulli 2020
    1. Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, et al. Ablation for hepatocellular carcinoma: beyond the standard indications. Medical Oncology 2020;37(4):23. [DOI: 10.1007/s12032-020-01348-y] - DOI - PubMed
Rethlefsen 2021
    1. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al, PRISMA-S Group. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Systematic Reviews 2021;10(1):39. [DOI: 10.1186/s13643-020-01542-z] - DOI - PMC - PubMed
RevMan 2025 [Computer program]
    1. Review Manager (RevMan). Version 9.1.0. The Cochrane Collaboration, 2025. Available at revman.cochrane.org.
Ricke 2019
    1. Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology 2019;71(6):1164-74. [DOI: 10.1016/j.jhep.2019.08.006] - DOI - PubMed
Rim 2021
    1. Rim CH, Park S, Shin IS, Yoon WS. Is the concurrent use of sorafenib and external radiotherapy feasible for advanced hepatocellular carcinoma? A meta-analysis. Cancers 2021;13(12):2912. [DOI: 10.3390/cancers13122912] - DOI - PMC - PubMed
Rimassa 2009
    1. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Review of Anticancer Therapy 2009;9(6):739-45. [DOI: 10.1586/ERA.09.41] - DOI - PubMed
Rose 2024
    1. Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights. JCO Oncology Practice 2024;20(8):1035-9. [DOI: 10.1200/OP.24.00189] - DOI - PubMed
Savović 2012a
    1. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157:429-38. - PubMed
Savović 2012b
    1. Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82. [DOI: 10.3310/hta16350] - DOI - PubMed
Savović 2018
    1. Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology 2018;187(5):1113-22. - PMC - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
Schünemann 2024
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence (last updated May 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Seidensticker 2023
    1. Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, et al. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. JHEP Reports 2023;5(5):100699. [DOI: 10.1016/j.jhepr.2023.100699] - DOI - PMC - PubMed
Serbanescu‐Kele Apor de Zalán 2022
    1. Serbanescu-Kele Apor de Zalán CM, Ruiter SJ, den Berg AP, Pennings JP, Jong KP. Outcomes after primary and repeat thermal ablation of hepatocellular carcinoma with or without liver transplantation. European Radiology 2022;32(6):4168-76. [DOI: 10.1007/s00330-021-08515-3] - DOI - PMC - PubMed
Shen 2013
    1. Shen A, Tang CY, Wang YF, Chen Y, Yan X, Zhang C, et al. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. Journal of Clinical Gastroenterology 2013;47(10):871-80. [DOI: 10.1097/MCG.0b013e3182a87cfd] - DOI - PubMed
Shi 2013
    1. Shi JH, Liu SZ, Wierød L, Scholz H, Anmarkrud JA, Huitfeldt HS, et al. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver. Journal of Surgical Oncology 2013;107(4):393-401. [DOI: 10.1002/jso.23224] - DOI - PubMed
Shin 2021
    1. Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan criteria: a systematic review and meta-analysis. Annals of Surgery 2021;273(4):656-66. [DOI: 10.1097/SLA.0000000000004350] - DOI - PubMed
Siegel 2023
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a Cancer Journal for Clinicians 2023;73(1):17-48. [DOI: 10.3322/caac.21763] - DOI - PubMed
Siegel 2025
    1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: a Cancer Journal for Clinicians 2025;75(1):10-45. [DOI: 10.3322/caac.21871] - DOI - PMC - PubMed
Simon 2005
    1. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics 2005;25(Suppl 1):S69-83. [DOI: 10.1148/rg.25si055501] - DOI - PubMed
Singal 2020
    1. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. Journal of Hepatology 2020;72(2):250-61. [DOI: 10.1016/j.jhep.2019.08.025] - DOI - PMC - PubMed
Sterne 2019
    1. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] - DOI - PubMed
Sung 2021
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 2021;71(3):209-49. [DOI: 10.3322/caac.21660] - DOI - PubMed
Tan 2018
    1. Tan HY, Wang N, Lam W, Guo W, Feng YB, Cheng YC. Targeting tumour microenvironment by tyrosine kinase inhibitor. Molecular Cancer 2018;17(1):43. [DOI: 10.1186/s12943-018-0800-6] - DOI - PMC - PubMed
Therasse 2000
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(3):205-16. [DOI: 10.1093/jnci/92.3.205] - DOI - PubMed
Thompson 1994
    1. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309(6965):1351-5. [DOI: 10.1136/bmj.309.6965.1351] - DOI - PMC - PubMed
Thorlund 2017
    1. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017. Available from ctu.dk/tsa/learn-more (accessed 13 May 2025).
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [DOI: 10.1186/1745-6215-8-16] - DOI - PMC - PubMed
TSA 2021 [Computer program]
    1. TSA – Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2021. ctu.dk/tsa/downloads/.
Tsukui 2012
    1. Tsukui Y, Mochizuki H, Hoshino Y, Kawakami S, Kuno T, Fukasawa Y, et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepato-gastroenterology 2012;59(120):2536-9. [DOI: 10.5754/hge12059] - DOI - PubMed
Ueshima 2020
    1. Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, et al. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer 2020;9(5):583-95. [DOI: 10.1159/000508724] - DOI - PMC - PubMed
Vennarecci 2016
    1. Vennarecci G, Grazi GL, Sperduti I, Busi Rizzi E, Felli E, Antonini M, et al. ALPPS for primary and secondary liver tumors. International Journal of Surgery 2016;30:38-44. [DOI: 10.1016/j.ijsu.2016.04.031] - DOI - PubMed
Viveiros 2019
    1. Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers 2019;11(8):1085. [DOI: 10.3390/cancers11081085] - DOI - PMC - PubMed
Vogel 2022
    1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400(10360):1345-62. [DOI: 10.1016/S0140-6736(22)01200-4] - DOI - PubMed
Vogel 2023
    1. Vogel A, Kelley RK, Johnson P, Merle P, Yau T, Kudo M, et al. Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review. Liver Cancer 2023;12(4):372-91. [DOI: 10.1159/000529173] - DOI - PMC - PubMed
Vogl 2006
    1. Vogl TJ, Mack M, Eichler K, Lehnert T, Nabil M. Effect of laser-induced thermotherapy on liver metastases. Expert Review of Anticancer Therapy 2006;6(5):769-74. [DOI: 10.1586/14737140.6.5.769] - DOI - PubMed
Wang 2020
    1. Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients. Annals of Surgery 2020;271(3):534-41. [DOI: 10.1097/SLA.0000000000002942] - DOI - PubMed
Wang 2024
    1. Wang L, Lin L, Zhou W. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: a meta-analysis. Pharmacology & Therapeutics 2024;257:108634. [DOI: 10.1016/j.pharmthera.2024.108634] - DOI - PubMed
Ware 1992
    1. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83. - PubMed
Wei 2022
    1. Wei MC, Zhang YJ, Chen MS, Chen Y, Lau WY, Peng ZW. Adjuvant sorafenib following radiofrequency ablation for early-stage recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Frontiers in Oncology 2022;12:868429. [DOI: 10.3389/fonc.2022.868429] - DOI - PMC - PubMed
Weis 2013
    1. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No: CD003046. [DOI: 10.1002/14651858.CD003046.pub3] - DOI - PMC - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] - DOI - PubMed
Wetterslev 2009
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86. [DOI: 10.1186/1471-2288-9-86] - DOI - PMC - PubMed
Wetterslev 2017
    1. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology 2017;17(1):39. [DOI: 10.1186/s12874-017-0315-7] - DOI - PMC - PubMed
WHO 1995
    1. World Health Organization (WHO). The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Social Science & Medicine 1995;41(10):1403-9. [DOI: 10.1016/0277-9536(95)00112-k] - DOI - PubMed
Williams 2004
    1. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. American Journal of Clinical Nutrition 2004;80(5):1106-22. [DOI: 10.1093/ajcn/80.5.1106] - DOI - PubMed
Wu 2021
    1. Wu L, Zhou J, Zhou W, Huang XF, Chen Q, Wang W, et al. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. Pathology Research and Practice 2021;220:153270. [DOI: 10.1016/j.prp.2020.153270] - DOI - PubMed
Wu 2025
    1. Wu H, Lv S, Zhang R, Gu L, Xu J, Li C, et al. Next-generation flexible embolic systems: targeted transarterial chemoembolization strategies for hepatocellular carcinoma. Advanced Materials 2025 Apr 7 [Epub ahead of print]:e2503971. [DOI: 10.1002/adma.202503971] - DOI - PubMed
Xu 2022
    1. Xu Y, Zhang Y, Zheng CZ, Li C, Guo T, Xu Y. Thermal ablation versus hepatic resection for colorectal cancer with synchronous liver metastases: a propensity score matching study. European Radiology 2022;32(10):6678-90. [DOI: 10.1007/s00330-022-09080-z] - DOI - PubMed
Yan 2023
    1. Yan J, Wen Y, Deng M, Ye B, Liu X, Zhang L. Transarterial chemoembolization plus sorafenib versus transarterial chemoembolization alone for advanced hepatocellular carcinoma: an umbrella review of meta-analyses and systematic reviews. Journal of Hepatocellular Carcinoma 2023;10:1723-33. [DOI: 10.2147/JHC.S429352] - DOI - PMC - PubMed
Yang 1993
    1. Yang R, Sanghvi NT, Rescorla FJ, Kopecky KK, Grosfeld JL. Liver cancer ablation with extracorporeal high-intensity focused ultrasound. European Urology 1993;23(Suppl 1):17-22. [DOI: 10.1159/000474674] - DOI - PubMed
Yang 2019
    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology & Hepatology 2019;16(10):589-604. [DOI: 10.1038/s41575-019-0186-y] - DOI - PMC - PubMed
Yang 2020a
    1. Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 2020;371:m3544. [DOI: 10.1136/bmj.m3544] - DOI - PubMed
Yang 2020b
    1. Yang Z, Feng J, Xiao L, Chen X, Yao Y, Li Y, et al. Tumor-derived peptidoglycan recognition protein 2 predicts survival and antitumor immune responses in hepatocellular carcinoma. Hepatology 2020;71(5):1626-42. [DOI: 10.1002/hep.30924] - DOI - PMC - PubMed
Yang 2024
    1. Yang LM, Wang HJ, Li SL, Gan GH, Deng WW, Chang YS, et al. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors. World Journal of Gastroenterology 2024;30(11):1533-44. [DOI: 10.3748/wjg.v30.i11.1533] - DOI - PMC - PubMed
Yeo 2024
    1. Yeo YH, Kang YN, Chen C, Lee TY, Yeh CC, Huang TW, et al. Liver resection had better disease-free survival rates compared with radiofrequency ablation in hepatocellular carcinoma: a meta-analysis based on randomized clinical trials. International Journal of Surgery 2024;110(11):7225-33. [DOI: 10.1097/JS9.0000000000001943] - DOI - PMC - PubMed
Yin 2018
    1. Yin Z, Jin H, Ma T, Zhou Y, Yu M, Jian Z. A meta-analysis of long-term survival outcomes between surgical resection and radiofrequency ablation in patients with single hepatocellular carcinoma ≤ 2 cm (BCLC very early stage). International Journal of Surgery 2018;56:61-7. [DOI: 10.1016/j.ijsu.2018.04.048] - DOI - PubMed
Yoo 2021
    1. Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: a murine model study. Clinical and Molecular Hepatology 2021;27(1):144-56. [DOI: 10.3350/cmh.2020.0095] - DOI - PMC - PubMed
Yuan 2021
    1. Yuan P, Wang F, Zhu G, Chen B. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma. Investigational New Drugs 2021;39(5):1383-8. [DOI: 10.1007/s10637-021-01101-w] - DOI - PubMed
Zeng 2022
    1. Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology 2022;150:216-24. [DOI: 10.1016/j.jclinepi.2022.07.014] - DOI - PubMed
Zeng 2023
    1. Zeng H, Zhou C, Chen X, Hu L, Su K, Guo L, et al. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Clinical and Experimental Medicine 2023;23(6):2141-50. [DOI: 10.1007/s10238-023-00997-3] - DOI - PMC - PubMed
Zeng 2024
    1. Zeng X, Tao H, Dong Y, Zhang Y, Yang J, Xuan F, et al. Impact of three-dimensional reconstruction visualization technology on short-term and long-term outcomes after hepatectomy in patients with hepatocellular carcinoma: a propensity-score-matched and inverse probability of treatment-weighted multicenter study. International Journal of Surgery 2024;110(3):1663-76. [DOI: 10.1097/JS9.0000000000001047] - DOI - PMC - PubMed
Zhang 2019
    1. Zhang R, Lin XH, Liu HH, Ma M, Chen J, Chen J, et al. Activated hepatic stellate cells promote progression of post-heat residual hepatocellular carcinoma from autophagic survival to proliferation. International Journal of Hyperthermia 2019;36(1):253-63. [DOI: 10.1080/02656736.2018.1558459] - DOI - PubMed
Zhang 2020
    1. Zhang T, Huang W, Dong H, Chen Y. Trans-catheter arterial chemoembolization plus sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma? A systematic review and meta-analysis. Medicine 2020;99(29):e20962. [DOI: 10.1097/MD.0000000000020962] - DOI - PMC - PubMed
Zhang 2022
    1. Zhang Z, Wu Y, Zheng T, Chen X, Chen G, Chen H, et al. Efficacy of transarterial chemoembolization combined with molecular targeted agents for unresectable hepatocellular carcinoma: a network meta-analysis. Cancers 2022;14(15):3710. [DOI: 10.3390/cancers14153710] - DOI - PMC - PubMed
Zhang 2023
    1. Zhang W, Ouyang D, Huang Z, Che X. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: an updated meta-analysis and systematic review. Frontiers in Oncology 2023;13:1085166. [DOI: 10.3389/fonc.2023.108516] - DOI - PMC - PubMed
Zhao 2023
    1. Zhao XH, Li HL, Guo CY, Yao QJ, Xia WL, Hu HT. Downstaging and conversation strategy for advanced hepatocellular carcinoma with portal vein branch tumor thrombus: TACE, 125I seed implantation, and RFA for hepatocellular carcinoma with portal vein branch tumor thrombus. Journal of Hepatocellular Carcinoma 2023;10:231-40. [DOI: 10.2147/JHC.S392293] - DOI - PMC - PubMed
Zhaohui 2019
    1. Zhaohui Z, Shunli S, Bin C, Shaoqiang L, Yunpeng H, Ming K, et al. Hepatic resection provides survival benefit for selected intermediate-stage (BCLC-B) hepatocellular carcinoma patients. Cancer Research and Treatment 2019;51(1):65-72. [DOI: 10.4143/crt.2018.038] - DOI - PMC - PubMed
Zhong 2025
    1. Zhong BY, Fan W, Guan JJ, Peng Z, Jia Z, Jin H, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterology & Hepatology 2025;10(4):369-86. [DOI: 10.1016/S2468-1253(24)00247-4] - DOI - PubMed
Zhou 2018
    1. Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Medicinal Research Reviews 2018;38(2):741-67. [DOI: 10.1002/med.21455] - DOI - PubMed
Zhou 2021
    1. Zhou YZ, Yang Y, Zhou BY, Wang ZZ, Zhu RL, Chen X, et al. Challenges facing percutaneous ablation in the treatment of hepatocellular carcinoma: extension of ablation criteria. Journal of Hepatocellular Carcinoma 2021;8:625-44. [DOI: 10.2147/JHC.S298709] - DOI - PMC - PubMed
Zhu 2019
    1. Zhu FP, Rhim H. Thermal ablation for hepatocellular carcinoma: what's new in 2019. Chinese Clinical Oncology 2019;8(6):58. [DOI: 10.21037/cco.2019.11.03] - DOI - PubMed
Zhu 2025
    1. Zhu W, Fan C, Zhao Y, Liu Y, Cheng Y, Zhou W. Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets. Hepatology International 2025 Mar 29 [Epub ahead of print]. [DOI: 10.1007/s12072-025-10799-2] - DOI - PubMed

MeSH terms

LinkOut - more resources